EUGENOL AMELIORATES RHABDOMYOLYSIS-INDUCED ACUTE KIDNEY INJURY IN MICE
Abstract
ABSTRACT
Background: Acute kidney injury (AKI) is a common and dangerous consequence of rhabdomyolysis which occurs in 50% of the cases with 5-10% mortality. In recent studies, eugenol has been reported as anti-fungal, antihyperglycemic, analgesic, anti-bacterial, anti-pyretic, anti-inflammatory and anti-oxidant agent. This study aimed to investigate the protective activity of eugenol on rhabdomyolysis-induced acute kidney injury (AKI) in mice.
Methods: Male, 24 BALB/c mice were divided into 4 groups (controls, AKI, eugenol and ascorbic acid as positive control). Controls and AKI were given normal saline, Eugenol (100 mg/kg bw) and ascorbic acid (200mg/kg) were given orally eugenol and ascorbic acid respectively for four days. After water deprivation for 24 hours, all animals, except controls, were injected with glycerol (50% - 10 ml/kg body weight intra-muscularly). After another 24 hours, blood samples were collected and kidneys were dissected out for biochemical investigations (serum urea and creatinine) and histopathological examination.
Results: Serum urea and creatinine levels compared to controls were significantly elevated in AKI group (p < 0.001) and significantly decreased, in eugenol and ascorbic acid groups (p < 0.001) compared to AKI group. Histopathological examination revealed about 44% damage in the AKI group compared to the normal group (p < 0.001). Eugenol and ascorbic acid decreased the damage to 13% and 8% respectively compared to AKI group (p < 0.001). The tested compounds were found to reduce tubular cast formation.
Conclusion: Eugenol has protective effects on rhabdomyolysis-induced AKI in mice. Further studies are required for evaluation of protective role of this compound in AKI.
Downloads
Published
Issue
Section
License
Copyright (c) 2019 The Pakistan Journal of Medicine and Dentistry
This work is licensed under a Creative Commons Attribution 4.0 International License.
This is an open-access article distributed under the terms of the CreativeCommons Attribution License (CC BY) 4.0 https://creativecommons.org/licenses/by/4.0/